

# AD-HOC ANNOUNCEMENT pursuant to section 15 WpHG

## MeVis Medical Solutions AG announces preliminary figures for 2010

### Non-cash charges have one-time negative effect on company's earnings

**Bremen, March 8, 2011** – Based on its preliminary figures for 2010, MeVis Medical Solutions AG [ISIN: DE000A0LBF4], a leading software company in the field of image-based medicine, produced turnover of approximately EUR 14.4 million (previous year: EUR 13.9 million) and produced EBIT of EUR -6 million (previous year: EUR 1.6 million) as earnings were negatively affected by EUR 6.3 million in one-time, non-cash charges. EBIT before non-cash charges was EUR 0.3 million.

*Group EBIT of EUR -6 million burdened by non-cash charges totaling EUR 6.3 million*

The non-cash charges included an impairment charge of approximately EUR 5.5 million on intangible assets associated with the company's pulmonary CT business, which was acquired in 2008. This impairment charge included about EUR 4.3 million for the complete write-off of goodwill and some EUR 1.2 million for the amortized costs of the software, licenses and customer base obtained during the transaction. The intangible assets were depreciated due to lower than expected sales performance of associated products. However, the Executive Board expects market potential for these products and technologies in the mid and long-term. The other non-cash charge was due to an obligatory grant in the amount of EUR 0.8 million to be paid to a research partner, which increased the company's other expenses. In previous years, this obligatory grant had been noted as a financial obligation in the company's financial statements.

*Impairment charge of EUR 5.5 million associated with the Lung-CT business*

*Provision of EUR 0.8 million with regard to an obligatory grant to a research partner*

Further preliminary figures for the fiscal year just ended are available in the company's corporate news release, issued today. The complete consolidated financial statement, group management report and 2011 forecast will be released on April 19, 2011.

\*\*\*\*\*

*MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.*

*Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.*